Saturday 17 October 2026
Export SKYE’s income statement to Excel — free account
Skye Bioscience, Inc.
SKYE Healthcare Biotechnology
In the quarter to June 2026, EPS grew 38.6% and free cash flow grew 34.8%, each against the same quarter a year earlier.
1.55
0.04
−2.52%
Follow SKYE
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
0.42 | 0.69 | 0.12 | 2.05 | 3.38 | 2.46 | 0.74 | 0.84 | 16.32 | 3.30 |
Net Debt/EBITDA |
0.02 | 0.01 | 0.11 | 0.24 | 0.27 | 1.03 | (0.03) | 0.17 | 2.34 | 0.45 |
Debt/Assets |
0.00% | 42.18% | 69.54% | 19.39% | 34.85% | 15.47% | 20.29% | 36.62% | 0.00% | 0.00% |
Debt/Equity |
0.00 | (0.29) | (0.09) | 0.71 | 2.07 | 0.26 | (0.61) | (2.05) | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.01 | 0.81 | 0.21 | (5.73) | 0.92 | 0.76 | 0.65 | 0.37 | 0.95 | 0.77 |
Capex/Depreciation |
(0.17) | (0.52) | (0.07) | 0.00 | (0.01) | (0.14) | (0.05) | 12.16 | (0.27) | 0.49 |
Interest Coverage |
— | (5,513.14) | (49.50) | (6.63) | (8.90) | (10.20) | (27.53) | (38.33) | (40.29) | — |
| 184.06% | 127.65% | 200.65% | (14.01%) | (1,313.58%) | (269.90%) | (1,364.21%) | 1,464.81% | (80.48%) | (126.85%) | |
| (182.72%) | (939.88%) | (1,526.80%) | 53.20% | (281.07%) | (136.06%) | (205.43%) | (357.64%) | (62.73%) | (110.66%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
939.42% | 1,663.30% | 137.28% | 102.51% | (348.14%) | (147.25%) | 630.98% | 1,705.78% | (39.11%) | (282.63%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(375.16) | (239.36) | (65.14) | (89.17) | (52.52) | (32.30) | (46.01) | (9.63) | (5.59) | (8.61) |
Cash per Share |
10.77 | 18.89 | 30.66 | 27.14 | 21.44 | 44.21 | 4.50 | 11.80 | 15.00 | 5.19 |
Shareholders Equity per Share |
(152.73) | (57.15) | (256.80) | 8.11 | 3.91 | 28.85 | (10.84) | (2.43) | 14.94 | 4.04 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(152.73) | (57.15) | (256.80) | 8.11 | 3.91 | 28.85 | (10.84) | (2.43) | 14.94 | 4.04 |
Free Cash Flow |
(3.56) | (3.35) | (3.95) | (6.03) | (6.06) | (6.57) | (12.77) | (8.43) | (25.48) | (42.71) |
Working Capital |
(0.38) | (0.25) | (13.99) | 1.02 | 1.88 | 5.70 | (3.18) | (2.25) | 66.49 | 18.89 |
Capital Expenditures |
(0.01) | (0.02) | 0.00 | — | (0.01) | (0.09) | (0.03) | 5.52 | (0.25) | 0.35 |
Net Current Asset Value |
(1.49) | (0.80) | (15.57) | 0.55 | 0.44 | 5.62 | (3.18) | (2.42) | 66.22 | 18.80 |
| Other line items | ||||||||||
Quick Ratio |
0.15 | 0.33 | 0.12 | 1.89 | 3.14 | 2.30 | 0.10 | 0.74 | 15.77 | 3.14 |
Depreciation/Fixed assets |
6.93 | 27.14 | 17.68 | 315.40 | 74.78 | 7.16 | 6.88 | 10.49 | 0.63 | 0.80 |
Cash ROIC |
264.27% | 1,114.40% | 31.98% | (217.64%) | (157.20%) | (40.09%) | (14,286.58%) | (67.05%) | (18.66%) | (93.33%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(373.99) | (237.95) | (65.07) | (89.17) | (52.46) | (31.85) | (45.91) | (15.93) | (5.53) | (8.69) |
Capex per Share |
(1.17) | (1.41) | (0.07) | 0.00 | (0.06) | (0.45) | (0.10) | 6.30 | (0.05) | 0.07 |
Average Payables |
0.20 | 0.19 | 0.06 | 0.08 | 0.26 | 0.64 | 1.35 | 1.38 | 0.76 | 1.30 |
Average Assets |
1.92 | 0.44 | 1.26 | 1.98 | 2.33 | 6.26 | 9.48 | 10.53 | 42.35 | 50.54 |
Average Common Equity |
(1.90) | (3.24) | (9.57) | (7.51) | 0.50 | 3.16 | 1.43 | (2.57) | 33.01 | 44.09 |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates